AIMM Therapeutics Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Out of Business

  • Employees
  • 9

Employees

  • Latest Deal Type
  • Out of Business

AIMM Therapeutics General Information

Description

Developer of therapeutic human monoclonal antibodies designed to offer treatment of cancer and infectious diseases. The company's human monoclonal antibodies and antibody discovery platform couples proprietary knowledge of B cell immortalization with the isolation of promising antibodies from humans or animals, enabling healthcare organizations to provide patients with quality care in a cost-efficient manner.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • Meibergdreef 59
  • 1105 BA Amsterdam
  • Netherlands
+31 020
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Meibergdreef 59
  • 1105 BA Amsterdam
  • Netherlands
+31 020

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AIMM Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Out of Business 01-Feb-2022 Completed Out of Business
4. Later Stage VC 01-Jan-2018 Completed Generating Revenue
3. Later Stage VC 07-Jun-2013 Completed Generating Revenue
2. Seed Round 01-Jun-2009 $1.37M $1.37M Completed Startup
1. Joint Venture 01-Jan-2004 Completed Startup
To view AIMM Therapeutics’s complete valuation and funding history, request access »

AIMM Therapeutics Patents

AIMM Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2017119811-A1 Therapeutic anti-cd9 antibody Inactive 08-Jan-2016
EP-3313870-A1 Aml antigens and uses thereof Active 24-Jun-2015
EP-3313870-B1 Aml antigens and uses thereof Active 24-Jun-2015
WO-2016209079-A1 Aml antigens and uses thereof Inactive 24-Jun-2015
EP-3189077-A2 Hepatitis c virus specific antibody Inactive 05-Sep-2014 C07K16/118
To view AIMM Therapeutics’s complete patent history, request access »

AIMM Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AIMM Therapeutics FAQs

  • When was AIMM Therapeutics founded?

    AIMM Therapeutics was founded in 2004.

  • Where is AIMM Therapeutics headquartered?

    AIMM Therapeutics is headquartered in Amsterdam, Netherlands.

  • What is the size of AIMM Therapeutics?

    AIMM Therapeutics has 9 total employees.

  • What industry is AIMM Therapeutics in?

    AIMM Therapeutics’s primary industry is Drug Discovery.

  • Is AIMM Therapeutics a private or public company?

    AIMM Therapeutics is a Private company.

  • What is AIMM Therapeutics’s current revenue?

    The current revenue for AIMM Therapeutics is .

  • How much funding has AIMM Therapeutics raised over time?

    AIMM Therapeutics has raised $29.7M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process